Figure 3From: Nifedipine decreases sVCAM-1 concentrations and oxidative stress in systemic sclerosis but does not affect the concentrations of vascular endothelial growth factor or its soluble receptor 1Individual and median values of serum sVCAM-1 concentrations in control subjects (n = 20) and patients with systemic sclerosis (SSc) at baseline and after treatment with 60 mg nifedipine per day (n = 20).Back to article page